Metabolic Effects of Bariatric Surgery in Mouse Models of Circadian Disruption [PDF]
, 2015 Background/Objectives: Mounting evidence supports a link between circadian disruption and metabolic disease. Humans with circadian disruption (for example, night-shift workers) have an increased risk of obesity and cardiometabolic diseases compared with ...
Arble, Deanna M. +4 more
core +3 more sources
orlistat improves release of gut hormones increasing satiety in obese women
Ожирение и метаболизм, 2014 Orlistat, which reduces fat absorption by inhibiting intestinal lipase is a registered drug for obesity pharmacotherapy. Meta-analyzes indicate various positive metabolic effects of orlistat, including improvements in glucose and lipid metabolism ...
Teona Albertovna Shvangiradze
doaj +1 more source
Incretin secretion and glucose metabolism in morbidly obese patients in the early and late periods after biliopancreatic diversion [PDF]
Терапевтический архив, 2016 Aim. To estimate the parameters of glucose metabolism and to assess the secretion of incretins in patients after biliopancreatic diversion (BPD) for morbid obesity (MO) in the early and late postoperative periods. Subjects and methods.
I I Dedov +7 more
doaj +1 more source
Glucagon-Like Peptide-1 and Hypothalamic Regulation of Satiation: Cognitive and Neural Insights from Human and Animal Studies [PDF]
Diabetes & Metabolism JournalGlucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as blockbuster drugs for treating metabolic diseases. Glucagon-like peptide-1 (GLP-1) plays a pivotal role in glucose homeostasis by enhancing insulin secretion, suppressing glucagon ...
Joon Seok Park +2 more
doaj +1 more source
Renal experiences of bariatric surgery in patients with type 2 diabetes mellitus [PDF]
Терапевтический архив, 2018 The review addresses the questions of the literature devoted to the problem of the influence of bariatric surgery on the course of diabetic nephropathy in patients with diabetes mellitus type 2 after achieving a surgically induced remission.
I I Larina +3 more
doaj +1 more source
Biomedicines, 2022 Diabetes mellitus is the leading cause of chronic kidney disease, and about 30–40% of patients with diabetes will develop kidney disease. Incretin hormones have received attention during the past three decades not only as a pharmacotherapy for the ...
Tomislav Bulum
doaj +1 more source
The cardiovascular safety of incretin-based therapies: a review of the evidence [PDF]
, 2013 Cardiovascular disease (CVD) is a leading cause of morbidity and mortality in people with diabetes and therefore managing cardiovascular (CV) risk is a critical component of diabetes care. As incretin-based therapies are effective recent additions to the
Petrie, J.R.
core +2 more sources
, 2020 Incretins, bile acids and the gut microbiome are involved in the pathophysiology of obesity and type 2 diabetes. The incretins glucagon-like peptide-1 and glucose-dependent-insulinetrophic polypeptide, both influence beta-cell function, insulin and ...
N. V. Olst +6 more
semanticscholar +1 more source
Renal effects of glucagon-like peptide receptor agonists in patients with type 1 diabetes mellitus [PDF]
Терапевтический архив, 2018 The purpose of our study is to assess the effects of glucagon-like peptide-1 receptor agonists (GLP-1R agonists) on early markers of kidney damage in patients with type 1 diabetes mellitus (DM). Materials and methods.
O K Vikulova +6 more
doaj +1 more source
Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors [PDF]
, 2009 BACKGROUND: Type 2 diabetes is a chronic, progressive disease with a multi-faceted pathophysiology. Beyond the known defects of insulin resistance and beta-cell insufficiency, derangement of incretin hormones normally produced from the gut wall in ...
Berneis, K +4 more
core +1 more source